Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the ...

Healthcare stocks can provide growth and consistent returns through a variety of market cycles. Eli Lilly has a storied ...

Now, it’s worth noting Stock Advisor's total average return is 1,072% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Walmart Pharmacies to offer weight-loss drug making obesity treatment more accessible for millions nationwide.

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...

India’s GLP-1 drug market is poised for explosive growth, outpacing global trends and positioning domestic pharma giants to challenge multinational dominance.

Though Novo Nordisk and Lilly already dominate the market, demand is so great for these products that there's room for others ...

What's better than investing in a stock with a promising outlook? Investing in a beaten-down stock with a promising outlook.

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Eli Lilly has once again delivered extraordinary financial results, powered by its highly successful diabetes and obesity treatments. The pharmaceutical giant's third-quarter performance has left ...

M·A·C Cosmetics will debut in select U.S. Sephora locations and at Sephora at Kohl’s in early 2026, expanding its domestic retail footprint ...